A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy

Trial Profile

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEURO-TTR
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2017 According to an Ionis Pharmaceuticals media release, new data from this trial were presented at the 142nd annual meeting of the American Neurological Association (ANA) 2017.
    • 15 Oct 2017 Results published in an Ionis Pharmaceuticals Media Release
    • 11 Aug 2017 Status changed from active, no longer recruiting to completed, according to an Ionis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top